Vitamin D3 – DACOM

2000I.U (50µg)+ inulin

The effect of DACOM D3 vitamin on:

Musculoskeletal system
-regulates bone metabolism, the level of phosphorus and calcium in the blood, bone remodeling, regulates the secretion of PTH.1,2

– has a favorable effect on increasing muscle mass and strength, aerobic capacity and shortens the time required for muscle recovery. 3

– in myelopathy, hypotonia and in children with motor retardation. 4

Immune system and autoimmune diseases
Vitamin D3 shows an immunomodulatory effect and has positive effects on inflammatory diseases: -rheumatoid arthritis, multiple sclerosis, diabetes mellitus type 1, autoimmune diseases of the thyroid gland (Graves’ disease, Hashimoto’s thyroiditis).5

Respiratory system
Vitamin D3 deficiency supports the production of inflammatory mediators and reduces the functional capacity of the lungs.6 Vitamin D3 is associated with a lower incidence of acute viral infections of the respiratory tract in adults.7

Cardiovascular system
Vitamin D, with its already mentioned antiproliferative effect, prevents fibrosis and hypertrophy of the myocardium and has an antiatherosclerotic effect. It has an antihypertensive effect, and by reducing the incidence of diabetes, it indirectly has a protective effect on the cardiovascular system. 8

Nervous system
Low concentrations of vitamin D3 are associated with depression. Alzheimer’s disease, dementia, cognitive decline and other forms of neurodegenerative disorders are associated with physiological concentrations of 25(OH)D in the blood.9

Metabolic syndrome
Vitamin D deficiency is associated with reduced insulin release, insulin resistance and type 2 diabetes. It affects blood lipid levels and body weight. 10

Oncological diseases
The positive effect of vitamin D3 on the differentiation and inhibition of cell proliferation (both malignant and normal) is the cause of its protective effect against malignant tumors. Most studies have confirmed the association of lower 25(OH)D3 concentrations with a higher incidence of colon cancer.
It is emphasized that the role of vitamin D3 in modulating the course of malignant diseases and reducing mortality from them is more significant than its role in reducing the incidence of those diseases.


years (age) Upper limit of intake that is considered safe (I.U per day)
0-1 1000
1-10 2000
Older than 11 years and adults 4000

The European Food Safety Authority and the Institute of Medicine (IOM) have determined the upper limit of vitamin D3 intake that is considered safe.


INULIN – prebiotic
Inulin is a plant polymer, classified as a prebiotic due to its positive effect on intestinal microflora. Inulin affects the growth of bifidobacteria. The beneficial effects of bifidobacteria include: inhibition of the growth of pathogenic bacteria, stimulation of components of the immune system and assistance in the absorption of certain ions and the synthesis of B vitamins. Inulin improves bioavailability and mineral balance. It is believed that the fermentation of inulin leads to acidification of the contents of the columns, which results in an increase in the concentration of ionized minerals, especially calcium and magnesium. These findings led scientists to consider the effect of inulin on bone density.


Recommended use of the product:
Adults and children over 6 years of age take one capsule once a day or according to the doctor’s advice.

The product must be used under medical supervision. It is not recommended for people with hypercalcemia and hyperparathyroidism. Excessive use may cause side effects and a doctor’s consultation should be sought. The product is not suitable as the only source of food for the people for whom it is intended!

The product should not be used by people who are hypersensitive to any of the product’s ingredients. The product is not intended for children under 6 years old!

Storage method:
Keep out of the reach of children. Store in the original packaging, protected from light and moisture at a temperature of 25oC.

Approved by the Ministry of Health of the Republic of Serbia
Decision number: 13426/2018. From 02.10.2018